Search results for "STAGE"

showing 10 items of 1393 documents

Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer

2018

Background: Serum levels of neutrophils, platelets, and lymphocytes have been recognized as factors related to poor prognosis for many solid tumors, including bladder cancer (BC). Objective: To evaluate the prognostic role of the combination of the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and lymphocyte/monocyte ratio (LMR) in patients with high-risk non–muscle-invasive urothelial BC (NIMBC). Design, setting, and participants: A total of 1151 NMIBC patients who underwent first transurethral resection of the bladder tumor (TURBT) at 13 academic institutions between January 1, 2002 and December 31, 2012 were included in this analysis. The median follow-up was 48 mo.…

OncologyMaleBladder cancer; Lymphocyte/monocyte ratio; Neutrophil/lymphocyte ratio; Platelet/lymphocyte ratio; Prognosis; Aged; Biomarkers Tumor; Blood Platelets; Carcinoma Transitional Cell; Cystectomy; Disease Progression; Female; Follow-Up Studies; Humans; Inflammation; Lymphocyte Count; Lymphocytes; Male; Monocytes; Neutrophils; Prognosis; Risk Factors; Urinary Bladder NeoplasmsNeutrophilsmedicine.medical_treatmentLymphocyte:Medicina Básica [Ciências Médicas]Prognosis.030232 urology & nephrologyMonocyteMonocytesSettore MED/24 - Urologia0302 clinical medicineRisk FactorsLymphocytesStage (cooking)Framingham Risk ScoreTumorNeutrophilBladder cancerPrognosis3. Good healthmedicine.anatomical_structureOncology030220 oncology & carcinogenesisNeutrophil/lymphocyte ratioCiências Médicas::Medicina BásicaDisease ProgressionLymphocyteFemalemedicine.symptomHumanBlood Plateletsmedicine.medical_specialtyPlatelet/lymphocyte ratioPrognosiUrologyInflammationCystectomyFollow-Up StudieCystectomy03 medical and health sciencesInternal medicinemedicineBiomarkers TumorHumansRadiology Nuclear Medicine and imagingLymphocyte CountAgedInflammationCarcinoma Transitional CellBladder cancerScience & Technologybusiness.industryProportional hazards modelRisk FactorCarcinomaLymphocyte/monocyte ratioImmunotherapymedicine.diseaseUrinary Bladder NeoplasmsBlood PlateletSurgeryTransitional CellbusinessBiomarkersFollow-Up Studies
researchProduct

Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of …

2011

Purpose The purpose of this study was to develop accurate models and nomograms to predict local recurrence, distant metastases, and survival for patients with locally advanced rectal cancer treated with long-course chemoradiotherapy (CRT) followed by surgery and to allow for a selection of patients who may benefit most from postoperative adjuvant chemotherapy and close follow-up. Patients and Methods All data (N = 2,795) from five major European clinical trials for rectal cancer were pooled and used to perform an extensive survival analysis and to develop multivariate nomograms based on Cox regression. Data from one trial was used as an external validation set. The variables used in the ana…

OncologyMaleCancer ResearchColorectal cancerMESH : AgedKaplan-Meier EstimateMESH : Randomized Controlled Trials as Topiclaw.invention[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineRandomized controlled triallawMESH : FemaleStage (cooking)Neoplasm MetastasisMESH: Models TheoreticalMESH : Rectal NeoplasmsSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIARandomized Controlled Trials as TopicMESH: Aged0303 health sciencesMESH: Middle AgedMESH : Neoplasm Recurrence LocalAge FactorsMiddle AgedMESH : Adult3. Good healthEuropeOncology030220 oncology & carcinogenesisMESH : Neoplasm MetastasisFemaleMESH: Neoplasm Recurrence LocalAdultmedicine.medical_specialtyMESH : Sex FactorsMESH : MaleMESH : Europe[SDV.CAN]Life Sciences [q-bio]/CancerMESH : Kaplan-Meier Estimate03 medical and health sciencesRECTAL CANCERSex FactorsMESH: Sex FactorsInternal medicinemedicineHumansMESH : Middle AgedSurvival analysisMESH: Kaplan-Meier Estimate030304 developmental biologyAgedMESH: Age FactorsMESH: HumansProportional hazards modelbusiness.industryRectal NeoplasmsMESH : Models TheoreticalMESH : HumansMESH: Rectal NeoplasmsMESH: AdultNomogramModels Theoreticalmedicine.diseaseMESH: Neoplasm MetastasisMESH: MaleSurgeryClinical trialMESH: Randomized Controlled Trials as TopicMESH : Age FactorsMESH: EuropeNeoplasm Recurrence LocalbusinessMESH: FemaleChemoradiotherapy
researchProduct

Multi-state relative survival modelling of colorectal cancer progression and mortality.

2015

Abstract Accurate identification of factors associated with progression of colorectal cancer remains a challenge. In particular, it is unclear which statistical methods are most suitable to separate the effects of putative prognostic factors on cancer progression vs cancer-specific and other cause mortality. To address these challenges, we analyzed 10 year follow-up data for patients who underwent curative surgery for colorectal cancer in 1985–2000. Separate analyses were performed in two French cancer registries. Results of three multivariable models were compared: Cox model with recurrence as a time-dependent variable, and two multi-state models, which separated prognostic factor effects …

OncologyMaleCancer Researchmedicine.medical_specialtyEpidemiologyColorectal cancer01 natural sciencesCancer recurrence010104 statistics & probability03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansRegistries0101 mathematicsStage (cooking)AgedNeoplasm StagingModels StatisticalMulti stateRelative survivalbusiness.industryProportional hazards modelCancermedicine.diseasePrognosis3. Good healthSurgerySurvival RateOncology030220 oncology & carcinogenesisCurative surgeryDisease ProgressionFemaleNeoplasm Recurrence LocalbusinessColorectal NeoplasmsCancer epidemiology
researchProduct

Tumor mutational burden on cytological samples: A pilot study.

2020

Background Immune-checkpoint inhibitors (ICIs) represent an important treatment option for patients who have advanced stage non-small cell lung cancer (NSCLC). Currently, evaluation of the expression level of programmed death-ligand 1 (PD-L1) has proven highly successful as a positive predictive biomarker for ICIs. In addition to PD-L1, other promising predictive biomarkers are emerging, including high tumor mutational burden (TMB-H). However, measuring TMB-H remains challenging for several reasons, among which is the difficulty in obtaining adequate tissue material from NSCLC patients. There are no data in the current literature regarding the possibility of adopting cell blocks (CBs) for T…

OncologyMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsCytological TechniquesDNA Mutational Analysis030209 endocrinology & metabolismPilot Projects03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungmedicineBiomarkers TumorHumansLung cancerPredictive biomarkerAgedRetrospective Studiesnext generation sequencingTMBbusiness.industryAdvanced stageTreatment optionsHigh-Throughput Nucleotide SequencingIon semiconductor sequencingAmpliconmedicine.diseasePrognosislung cancerOncology030220 oncology & carcinogenesisMutationcytologyTissue materialFemaleimmunotherapyNon small cellbusinessFollow-Up StudiesCancer cytopathologyReferences
researchProduct

Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry.

2009

The Italian Neuroblastoma Registry was investigated to describe 781 children with neuroblastoma experiencing tumour recurrence (424 progressions and 357 relapses). Ten-year overall survival (OS) was 6.8% (95% confidence interval (CI) 4.3-10.0) after progression and 14.4% (95% CI 10.5-18.9) after relapse. For both circumstances, OS was better for age at diagnosis <18 months, less advanced International Neuroblastoma Staging System (INSS) stage, normal lactate dehydrogenase (LDH) serum level, normal MYCN gene status (P<0.001) and a non-abdominal primary site (P=0.034 for progression, and P=0.004 for relapses). A local type of recurrence had a significantly better outcome only in case of relap…

OncologyMaleCancer Researchmedicine.medical_specialtyPediatricsRisk factors MYCNNeuroblastomaSurvival relapse progressionRisk FactorsNeuroblastomaInternal medicinemedicineHumansStage (cooking)Risk factorChildSurvival analysisRetrospective StudiesSalvage Therapybusiness.industryCancerInfantRetrospective cohort studymedicine.diseaseSurvival AnalysisConfidence intervalOncologyItalyChild PreschoolCohortDisease ProgressionFemaleNeoplasm Recurrence LocalbusinessChildhood cancerEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Prophylactic cranial irradiation in stage IV small cell lung cancer

2019

Background: Due to conflicting results between major trials the role of prophylactic cranial irradiation (PCI) in stage IV small cell lung cancer (SCLC) is controversial.Methods: We obtained a list of 13 European experts from both the European Society for Therapeutic Radiation Oncology (ESTRO) and the International Association for the Study of Lung Cancer (IASLC). The strategies in decision making for PCI in stage IV SCLC were collected. Decision trees were created representing these strategies. Analysis of consensus was performed with the objective consensus methodology.Results: The factors associated with the recommendation for the use of PCI included the fitness of the patient, young age…

OncologyMaleESTRO; Expert opinion; IASLC; PCI; Small cell lung cancer; Stage IV; Hematology; Oncology; Radiology Nuclear Medicine and ImagingLung Neoplasmsmedicine.medical_treatmentMedizin030218 nuclear medicine & medical imaging0302 clinical medicineQUALITY-OF-LIFENuclear Medicine and ImagingESTRO610 Medicine &amp; healthStage IVHematologyBrain NeoplasmsRadiation OncologistsPCIHematologyMiddle AgedProgression-Free SurvivalExpert opinion030220 oncology & carcinogenesisFemaleTRIALNon small cellRadiologyAdultmedicine.medical_specialtyDecision Making03 medical and health sciencesInternal medicinemedicineHumansIASLCRadiology Nuclear Medicine and imagingLung cancerAgedNeoplasm StagingChemotherapySmall cell lung cancerbusiness.industryPatient Selectionmedicine.diseaseONCOLOGYSmall Cell Lung CarcinomaYoung ageConventional PCIProphylactic cranial irradiationCranial IrradiationbusinessStage ivRadiotherapy and Oncology
researchProduct

The evolutionary scenario of hepatocellular carcinoma in Italy: an update

2017

Background and aims Epidemiology of hepatocellular carcinoma is changing worldwide. This study aimed at evaluating the changing scenario of etiology, presentation, management and prognosis of hepatocellular carcinoma in Italy during the last 15 years. Methods Retrospective analysis of the ITA.LI.CA (Italian Liver Cancer) database including 5192 hepatocellular carcinoma patients managed in 24 centers from 2000 to 2014. Patients were divided into three groups according to the date of cancer diagnosis (2000-2004, 2005-2009 and 2010-2014). Results The main results were: 1) progressive patient aging; 2) progressive expansion of non-viral cases and, namely, of “metabolic” hepatocellular carcinoma…

OncologyMaleEtiologyDatabases FactualRadiofrequency ablationmedicine.medical_treatmentlaw.invention0302 clinical medicinelawEpidemiologyepidemiology; hepatocellular carcinoma; survival; treatment; HepatologyAged 80 and overSurveillancetreatmentLiver Neoplasmshepatocellular carcinomaMiddle AgedPrognosisItaly030220 oncology & carcinogenesisHepatocellular carcinomaCatheter Ablation030211 gastroenterology & hepatologyFemaleepidemiology; hepatocellular carcinoma; survival; treatmentepidemiologyalpha-FetoproteinsLiver cancerAdultmedicine.medical_specialtyCarcinoma Hepatocellularsurvival03 medical and health sciencesYoung AdultAge DistributionInternal medicinemedicineHumansSex DistributionAgedNeoplasm StagingRetrospective StudiesCirrhosiHepatologybusiness.industryCancer stageSettore MED/09 - MEDICINA INTERNACancermedicine.diseaseSurgeryepidemiology; hepatocellular carcinoma; survival; treatment; Adult; Age Distribution; Aged; Aged 80 and over; Carcinoma Hepatocellular; Catheter Ablation; Databases Factual; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Sex Distribution; Young Adult; alpha-FetoproteinsEtiologyPercutaneous ethanol injectionbusiness
researchProduct

Detection and characterization of tumor hypoxia using pO2 histography.

2007

Data from 125 studies describing the pretreatment oxygenation status as measured in the clinical setting using the computerized Eppendorf pO2 histography system have been compiled in this article. Tumor oxygenation is heterogeneous and severely compromised as compared to normal tissue. Hypoxia results from inadequate perfusion and diffusion within tumors and from a reduced O2 transport capacity in anemic patients. The development of tumor hypoxia is independent of a series of relevant tumor characteristics (e.g., clinical size, stage, histology, and grade) and various patient demographics. Overall median pO2 in cancers of the uterine cervix, head and neck, and breast is 10 mm Hg with the ov…

OncologyMalePathologymedicine.medical_specialtyTime FactorsPhysiologyClinical BiochemistryUterine Cervical NeoplasmsBreast NeoplasmsBiochemistryInternal medicineNeoplasmsMedicineHumansOximetryStage (cooking)Neoplasm MetastasisHypoxiaMolecular BiologyGeneral Environmental ScienceTumor hypoxiabusiness.industryHistologyCell BiologyOxygenationHypoxia (medical)Tumor OxygenationPrognosisOxygenHead and Neck NeoplasmsGeneral Earth and Planetary SciencesFemaleHemoglobinmedicine.symptombusinessPerfusionSoftwareAntioxidantsredox signaling
researchProduct

Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma

2016

Background Prognostic assessment in patients with hepatocellular carcinoma (HCC) remains controversial. Using the Italian Liver Cancer (ITA.LI.CA) database as a training set, we sought to develop and validate a new prognostic system for patients with HCC. Methods and Findings Prospective collected databases from Italy (training cohort, n = 3,628; internal validation cohort, n = 1,555) and Taiwan (external validation cohort, n = 2,651) were used to develop the ITA.LI.CA prognostic system. We first defined ITA.LI.CA stages (0, A, B1, B2, B3, C) using only tumor characteristics (largest tumor diameter, number of nodules, intra- and extrahepatic macroscopic vascular invasion, extrahepatic metas…

OncologyMaleTime FactorsDatabases FactualCancer Treatmentlcsh:MedicinePredictive Value of TestPediatricsBiochemistryGeographical locationsNeoplasms Multiple PrimaryDecision Support Technique0302 clinical medicineInterquartile rangeRetrospective StudieMultiple PrimaryRisk FactorsNeoplasmsMedicine and Health SciencesEthnicitiesPublic and Occupational HealthLiver DiseasesLiver NeoplasmsChild HealthGeneral MedicineMiddle AgedPrognosisItalian PeopleTumor BurdenQuartileOncologyCirrhosisItalyLiver Neoplasm030220 oncology & carcinogenesisPredictive value of testsCohortPerspectiveHong Kong030211 gastroenterology & hepatologyFemaleSurvival Analysialpha-FetoproteinsHumanBiotechnologymedicine.medical_specialtyCarcinoma HepatocellularAsiaTime FactorSettore MED/12 - GASTROENTEROLOGIAAged; Carcinoma Hepatocellular; Databases Factual; Decision Support Techniques; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms Multiple Primary; Predictive Value of Tests; Reproducibility of Results; Retrospective Studies; Risk Assessment; Risk Factors; Survival Analysis; Taiwan; Time Factors; Tumor Burden; alpha-Fetoproteins; Biotechnology; Biochemistry; Molecular Biology; Cell BiologyTaiwanReproducibility of ResultGastroenterology and HepatologyCarcinomasRisk AssessmentDecision Support Techniques03 medical and health sciencesDatabasesDiagnostic MedicinePredictive Value of TestsInternal medicineGastrointestinal TumorsmedicineHumansNeoplasm Invasivenessalpha-FetoproteinMolecular BiologySurvival analysisFactualAgedNeoplasm StagingRetrospective StudiesNeoplasm InvasivenePerformance statusbusiness.industryRisk Factorlcsh:RCarcinomaCancers and NeoplasmsReproducibility of ResultsRetrospective cohort studyHepatocellularHepatocellular CarcinomaCell BiologySurvival AnalysisBCLC StageSurgeryPeople and PlacesPopulation Groupingsbusiness
researchProduct

Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.

2019

To compare toxicity and response of docetaxel chemotherapy between metastatic hormone-sensitive prostate cancer (mHSPC) and castration-resistant metastatic prostate cancer (mCRPC) patients of the same therapeutic era for assessing of upfront docetaxel against the benchmark of docetaxel in the castrate resistant stage in the setting outside of clinical trials.A prospectively collected database of real-world prostate cancer patients receiving docetaxel was divided in mHSPC and mCRPC cases and retrospectively analyzed. Principal objectives were toxicity measured by the common criteria of adverse events terminology and response characterized by Prostate specific antigen decline and radiographic…

OncologyMalemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsUrologymedicine.medical_treatment030232 urology & nephrologyAntineoplastic AgentsDocetaxelSeverity of Illness Index03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicinemedicineHumansProspective StudiesStage (cooking)Adverse effectAgedNeoplasm StagingRetrospective StudiesChemotherapyPerformance statusbusiness.industryProstateMiddle AgedProstate-Specific Antigenmedicine.diseasePrognosisProgression-Free SurvivalClinical trialRadiographyProstate-specific antigenProstatic Neoplasms Castration-ResistantOncologyDocetaxelClinical Trials Phase III as Topic030220 oncology & carcinogenesisDisease ProgressionKallikreinsbusinessmedicine.drugUrologic oncology
researchProduct